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Clostridioides difficile is a Gram-positive pathogen that is one of the most common 
causes of health care-associated infections in the U.S. Because of its importance to human 
health, researchers are trying to understand risk factors for infection and identify new therapies 
to treat disease. A “healthy” gut microbiome has the ability to protect the host against 
colonization of C. difficile or other pathogens by providing colonization resistance. One 
proposed mechanism for colonization resistance is through competition for nutrients with 
pathogens by the members of the healthy microbiome. We tested whether competition for 
nutrients was important for colonization resistance in human fecal minibioreactor arrays 
(MBRAs), an in vitro model of C. difficile colonization resistance that can be used to culture 
fecal communities from different healthy humans. We found that C. difficile growth was limited 
when amino acids were depleted and that ability to metabolize proline, an amino acid shown to 
be important in mouse models of infection, was required for C. difficile to colonize in some fecal 
communities but not others.  As several previous studies point to proline as potentially important 
niche during human infections, these results provide further support for use of this model to 
understand factors important for C. difficile colonization that vary across fecal communities and 
can be used for further development of predictive models of important nutrient niches. Future 
       
studies that build upon this work could combine sequence data, metabolomics data, and 
compound and pathway enrichment analysis to begin developing models that predict important 
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Chapter I Literature Review 
1.1 Introduction 
Clostridioides difficile is a Gram-positive, rod-shaped, obligately anaerobic bacterium 
that can produce toxins and form spores highly resistant to extreme conditions (Rupnik et al., 
2009). Even though C. difficile has been characterized since 1935, it was not until the 1970s that 
there was evidence to indicate that C. difficile was pathogenic (Rodriguez et al., 2016). Ever 
since then till the end of the 20th century, the reported cases of C. difficile infection (CDI) 
increased slowly but steadily (Kelly & LaMont, 2008). In the early 2000s, rates of CDI began 
increasing significantly; of even more concern, was the rise of disease severity and morality rate 
(Kelly & LaMont, 2008). Because of these high rates of infection and severe disease, research 
has focused on understanding factors important for disease susceptibility to predict patients at 
risk for disease and to develop new therapies. In the rest of this review, I will highlight what is 
known about C. difficile infection, disease progression, and mechanisms for colonization 
resistance. 
1.2 Clostridioides difficile Infection 
1.2.1 History of C. difficile 
In 1935, C. difficile was first isolated from the stool of a healthy newborn infant by Hall 
and O’Toole (Hall & O’Toole, 1935). Its original genus name, Clostridium, was given because it 
was a member of the anaerobic, spore-forming Gram-positive bacteria; its species name, C. 
difficile, was given to acknowledge that it is difficult to isolate and culture (Kelly & LaMont, 
2008). Before the 1970s, there was no evidence to indicate that C. difficile was pathogenic and it 
was considered a member of normal human fecal microbiome (Rodriguez et al., 2016). In 1978, 
scientists investigating the cause of pseudomembranous colitis (PMC), a severe form of colitis in 
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which inflammation leads to pseudomembranes in the colon, established the association of C. 
difficile with PMC and demonstrated that previous antibiotic therapy is a key risk factor for 
susceptibility to infection (Bartlett et al., 1978; George et al., 1978). Ever since then till the end 
of 20th century, the reported cases of C. difficile infection (CDI) increased slowly but steadily 
(Kelly & LaMont, 2008). In the early 2000s, rates of CDI began increasing significantly; of even 
more concern, was the rise of disease severity and morality rate (Kelly & LaMont, 2008). This 
change in incidence, disease severity and mortality correlated with the emergence of new 
hypervirulent strains of C. difficile in North America and Europe that were classified as North 
American Pulsed Field Type 1 and PCR ribotype 027 (NAP-1/027) (McDonald et al., 2005). 
Several factors were hypothesized to contribute to the prevalence and severity of infection 
caused by this ribotype, including its ability to produce higher amounts of toxin, resistance to 
fluoroquinolones, production of binary toxin, hypersporulation and increased ecological fitness 
(Goudarzi et al., 2014; Kelly & LaMont, 2008; Robinson et al., 2014). While the prevalence of 
this ribotype has subsided to some extent, possibly due to reduction in usage of fluoroquinolones 
(Jassem et al., 2016; Wilcox et al., 2012), rates of C. difficile caused by multiple ribotypes 
remain high and are a significant concern for public health (Centers for Disease Control and 
Prevention (U.S.), 2019). 
In the last decade, the increasing amount of sequence data from C. difficile and other 
sequenced Clostridium led to the recognition that the genus Clostridium was too broad and 
included organisms that were not closely related enough to be members of the same genus. In 
2016, Lawson and coworkers proposed the re-classification of “Clostridium” difficile to 
“Clostridioides” difficile (Lawson et al., 2016; Oren & Rupnik, 2018). While there are still many 
authors that use the original name Clostridium difficile, Clostridioides difficile has been used 
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with more frequency over the past five years and is one of two recognized names for C. difficile 
(Oren & Rupnik, 2018).  
1.2.2 Disease progression and pathogenesis 
C. difficile is a Gram-positive, rod-shaped, obligately anaerobic bacterium that can 
produce toxins and form spores highly resistant to extreme conditions (Rupnik et al., 2009). C. 
difficile spores are often present in soils and other environments and its potential reservoirs 
include infected individuals, asymptomatic carriers, healthcare workers and contaminated 
environments (Czepiel et al., 2019). CDI patients usually acquire C. difficile spores through 
fecal-oral route (Seekatz & Young, 2014). Its spores pass through the upper digestive tract to the 
small intestine where they germinate into vegetative cells (Kochan et al., 2018). Under 
permissive conditions, vegetative cells can colonize the large intestine, produce toxins and cause 
diseases (Kochan et al., 2018). The infection can lead to various symptoms from mild diarrhea 
and abdominal pain to pseudomembranous colitis, toxic megacolon and even death in more 
complicated cases. While many infections resolve on their own, ~25% patients experience 
recurrent rounds of C. difficile infection (Johnson, 2009). 
The major virulence factors produced by C. difficile are two exotoxins: ToxinA and 
ToxinB, which are encoded by tcdA and tcdB respectively, and are primarily responsible for the 
symptoms of CDI (Awad et al., 2014). These two genes are located in the pathogenicity locus as 
shown in Fig 1.1 (PaLoc), a 19.6 kb region of the chromosome that also contains accessory 
genes tcdC, tcdR and tcdE that encode proteins that regulate toxin production or toxin 
exportation (Awad et al., 2014; Braun et al., 1996). Both Toxin A and B belong to the large 
clostridial toxin (LCT) family which are monoglycosyltransferases (Carter et al., 2012). The 
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toxins act on target cells in the colon by glycosylation of Rho family GTPases, which results in 
an inactive conformation of the protein and therefore prevents the cellular activities that require 
the participation of Rho GTPases (Carter et al., 2012). Rho GTPases play important roles in 
many cellular processes, including the regulation of actin cytoskeleton assembly and 
organization (Pothoulakis, 2000). The intoxication of colonocytes causes disaggregation of 
filamentous actin and loss of structural integrity that results in death of intoxicated cells, which 
subsequently leads to epithelial cell disruption and impairment of cellular tight junctions (Carter 
et al., 2012; Pothoulakis, 2000). These effects together increase the intestinal permeability, 
which allows fluid accumulation that lead to diarrhea, a typical symptom of CDI in patients 
(Awad et al., 2014).  
In addition to the direct alteration of epithelium structure, toxin exposure also triggers the 
release of a number of chemokines and cytokines from epithelial cells and the migration of 
neutrophils to the site of infection (Voth & Ballard, 2005). The toxins could also activate mast 
cells and submucosal neurons following with the production of a variety of proinflammatory 
cytokines that lead to a profound inflammatory response (Awad et al., 2014). This response is an 
important characteristic of CDI and also correlated to the severity of host tissue damage (Awad 
et al., 2014). 
Other factors that contribute to C. difficile disease severity include the Surface Layer 
Protein (SLP), flagella, and a third toxin called C. difficile transferase (CDT) that is produced by 
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some clinical C. difficile isolates including ribotype 027 strains. CDT ADP-ribosylates actin, 
which leads to loss of function and disruption of the actin cytoskeleton (Chandrasekaran & Lacy, 
2017). Recent studies show that strains that produce CDT but do not produce TcdA or TcdB 
cause some intestinal hemorrhage, inflammation and fluid accumulation, but do not cause 
diarrhea (reviewed in Chandrasekaran & Lacy, 2017). Strains that only produce CDT and not 
TcdA or TcdB have also been found in patients with symptomatic C. difficile infection, but this 
is not very common. SLP and flagella both contribute to activation of the immune system 
(Solomon, 2013). Altogether, the toxins and other virulence factors disrupt the epithelial barrier 
and activate the immune system to varying extents across patients which leads to the variation in 
disease severity observed. 
1.2.3 Epidemiology and risk factors of C. difficile infection  
In the past two decades, the incidence and severity of CDI has considerably increased and 
this can be attributed to the spread of the hypervirulent ribotypes and excessive use of antibiotics 
(Goudarzi et al., 2014). CDI has now become one of the most common hospital-acquired 
infections (Centers for Disease Control and Prevention (U.S.), 2019). Identifying populations 
under higher risk for infection and severe disease will help with diagnosis and treatment with 
CDI patients. The most important risk factors for developing CDI include people older than 65 
years old, male gender, antimicrobial therapy and prolonged duration of hospital stay (Goudarzi 
et al., 2014). In addition, populations with comorbidities or underlying conditions, such as 
immunodeficiency and HIV, inflammatory bowel diseases, neoplastic diseases, malnutrition, 
diabetes and cystic fibrosis are also considered high-risk populations for developing CDI (Lo 
Vecchio & Zacur, 2012). Among all these risk factors, the most common recognized risk factor 
is antimicrobial administration due to its disruption of indigenous gut microbiome; disruption of 
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the microbiome promotes C. difficile colonization (Goudarzi et al., 2014). A more complete 
description of how the gut microbiome typically resists C. difficile colonization is provided in 
more detail below. 
1.3 Colonization resistance of commensal gastrointestinal microbiome 
The gastrointestinal tract (GI) of humans is the harbor for trillions of microorganisms 
including bacteria, viruses, fungi and protozoa (Valdes et al., 2018). This collective community 
of microorganisms residing in the GI tract are referred to as the gut microbiota and this microbial 
community with their genomes are defined as gut microbiome (Valdes et al., 2018). After 
thousands of years of co-evolving, the microbiota developed an intricate, mutualistic relationship 
with its host (Bäckhed et al., 2005; Thursby & Juge, 2017). It has been estimated that the number 
of unique genes encoded by the gut microbiome can be over 100 times more than that of our own 
genome (Bäckhed et al., 2005). This large and diverse genomic content of gut microbiota allows 
it to provide various beneficial properties to the host, including assisting in maintaining the 
integrity of the mucosal barrier, development of the immune system, degradation of indigestible 
polysaccharides and providing colonization resistance (Thursby & Juge, 2017).  
Colonization resistance is the term used to describe the ability of a healthy gut 
microbiome to provide protection against pathogens (Vollaard & Clasener, 1994). There are 
several potential mechanisms through which the gut microbiome can convey colonization 
resistance. The gut microbiome can mediate colonization resistance directly, by effectively 
competing for available nutrients and/or adhesion receptors on the intestinal epithelium, or via 
the production of growth-inhibitory or toxic substances, or the microbiome could mediate 
colonization resistance indirectly via the stimulation of host immune defenses (Stecher & Hardt, 
2011). Studies in animal models and in vitro models have indicated that the indigenous 
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microbiome can inhibit C. difficile colonization (Borriello & Barclay, 1986; Wilson et al., 1981). 
Some specific mechanisms identified over the past several years are described below. 
1.3.1 Potential mechanisms of colonization resistance 
1.3.1.1 Inhibition of germination and growth through metabolism of bile salts by the 
gut microbiota  
Since C. difficile spreads in the form of spores, which do not produce toxins that cause 
diseases, it is necessary for C. difficile to germinate into vegetative cells and outgrow in the GI 
tract before it can exert any influence on the host. The gut microbiome can inhibit this 
germination process by modifying bile acids that enter the large intestine (Sorg & Sonenshein, 
2010).  
Primary bile acids are synthesized in the liver, including cholate and chenodeoxycholate 
(Sorg & Sonenshein, 2010). To make them impermeable to cell membranes and therefore 
maintain a higher concentration of bile acids in the bile and gut, these primary bile acids are 
conjugated with either taurine or glycine, which are released to the digestive tract in response to 
food ingestion (Reed & Theriot, 2021). Although most bile acids will be absorbed for 
reutilization, a low concentration of bile acids still reaches the large intestine (Northfield & 
McColl, 1973). The gut microbiome plays two important roles in the transformation of bile 
acids.  First, in the small intestine and proximal colon (cecum), the gut microbiome deconjugate 
bile acids by removing amino acids with bile salt hydrolase that is commonly encoded by gut 
bacteria (Ridlon et al., 2006).  Secondly, a few species in the gut microbiome metabolize these 
deconjugated primary bile acids through 7α-dehydroxylation, converting cholate to deoxycholate 
and chenodeoxycholate to lithocholate (Ridlon et al., 2006).  Therefore, the gut microbiome is 
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responsible for control the bile acids composition and ratio in the large intestine (Britton & 
Young, 2012).  
Interestingly, these bile acids have different effects on germination process. 
Taurocholate, glycocholate, cholate and deoxycholate stimulate the spore germination while 
taurochenodeoxycholate, glycocenodeoxycholate, chenodeoxycholate and lithocholate show 
inhibitory effects (Sorg & Sonenshein, 2008). Though deoxycholate acts as a germinant, it is 
highly toxic to vegetative cells and cell death can occur quickly after germination in its presence 
(Britton & Young, 2012). Thus, only when taurocholate, glycocholate, and/or cholate levels in 
the environment are higher than other bile acids will C. difficile will be able to germinate and 
persist (Britton & Young, 2012). Through mediation of bile acids composition and ratio, gut 
microbiome provide protection by interfering with C. difficile spore germination and inhibiting 
vegetative growth. 
1.3.1.2 Production of inhibitory metabolites 
In addition to bile acid transformation, there are other commensal bacterial activities that 
produce metabolites that contribute to colonization resistance against C. difficile, such as 
production of short-chain fatty acids (SCFAs). SCFAs, mainly acetate, propionate and butyrate, 
are the main metabolites produced by commensal bacteria via the fermentation of indigestible 
polysaccharides like fibers and resistant starch (Silva et al., 2020). In a recent study in mice fed 
with a microbiota accessible carbohydrates-supplemented diet, the level of vegetative C. difficile 
cells in the feces was significantly lower along with an increased concentration of acetate, 
propionate and butyrate (Hryckowian et al., 2018). Further testing indicated SCFAs can directly 
inhibit the bacterial growth of C. difficile (Hryckowian et al., 2018). Although these three SCFAs 
increase expression of tcdB in vitro, the overall toxin level is reduced due to the decreased levels 
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of vegetative cells (Hryckowian et al., 2018).  SCFAs also can lead to localized reduction of pH 
to lower than optimum pH for C. difficile growth, thus repressing the replication rate (Lawley & 
Walker, 2013). Additionally, there has been a recent study showing that butyrate can protect 
mice from C. difficile-induced colitis through reduction of intestinal permeability, inflammation 
and microbial translocation using an HIF-1 dependent mechanism (Fachi et al., 2019). This 
suggests gut microbiota produced SCFAs mediate colonization resistance not only via direct 
inhibitory effects, but also through regulating host intestinal structure and immune system 
function. 
Some members of the gut microbiota also contribute to colonization resistance by 
producing antimicrobial metabolites that can inhibit C. difficile growth. One group of metabolites 
of particular interest is bacteriocins, which are peptides released by bacteria that have narrow or 
broad-spectrum bactericidal effect against pathogens like C. difficile (Lawley & Walker, 2013). 
Bacteriocins with a narrow-spectrum selectively target C. difficile and have potential to be novel 
antibiotics that can cure CDI without disrupting the indigenous microbiome and colonization 
resistance (Lawley & Walker, 2013). 
1.3.2 Antibiotic disruption and impacts on the microbiome 
Antibiotic administration plays a key role in CDI, not only is it the main risk factor 
related to clinical cases, but also antibiotic administration is required to make most experimental 
animal models susceptible to CDI (Theriot & Young, 2014). Several studies have shown that 
antibiotics have profound effects on the composition of gut microbiota. Mice treated with an 
antibiotic cocktail (ampicillin, gentamicin, metronidazole, neomycin, and vancomycin) via 
drinking water or oral gavage result in at least 10-fold reduction in total bacterial load in fecal 
samples (Hill et al., 2010). Sequencing results of this study suggest that antibiotic-treatment 
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introduced dramatic changes in terms of bacterial composition and diversity of gut microbiota, 
especially significant decreases in the levels of Firmicutes (Hill et al., 2010). In a separate study, 
fecal samples collected from human participants who received ciprofloxacin therapy also showed 
reduction in the level of Ruminococcaceae and Lachnospiraceae families that belong to 
Firmicutes (Dethlefsen & Relman, 2011).  
The alteration of gut microbial community structure by antibiotics in turn results in 
changes of its metabolic functions, and therefore leads to changes in the metabolome. Mouse 
studies demonstrated that mice treated with streptomycin, gentamicin or ceftriaxone had drastic 
changes in metabolic profiles, including shifts in bile acids and amino acids metabolism, 
increases in oligosaccharides (sucrose, cellobiose, raffinose and stachyose), as well as decreases 
in monosaccharides (glucose, fructose, xylose and galactose) and SCFAs (Antunes et al., 2011; 
Zhao et al., 2013). It has been demonstrated that antibiotic treatment induces shifts in gut 
microbial metabolome and substances that potentially in favor of C. difficile sporulation and 
growth increase in abundance (Theriot et al., 2014). Taken together, antibiotics can alter gut 
microbial structure and metabolomic profile and therefore impair colonization resistance, thus 
increasing the susceptibility to C. difficile infection. 
1.3.3 Competition and nutrient-niche theory 
Another mechanism of colonization resistance is the competition for nutrients between 
the commensal microbiome and infecting C. difficile cells. This observation that colonic 
microflora suppresses C. difficile growth via competition for nutrients, including glucose, N-
acetylglucosamine and sialic acids, was first highlighted in 1988 by Wilson et al. (Wilson & 
Perini, 1988). Since then, further studies have pointed to competition for nutrients as an effective 
mechanism to inhibit C. difficile growth. One good example is colonization with non-toxigenic 
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strains of C. difficile. In gnotobiotic mice, colonization of nontoxigenic C. difficile strain prior to 
challenge of toxigenic C. difficile strain successfully protected from disease. In human patients,  
oral administration of spores of nontoxigenic C. difficile significantly reduced the incidence of 
CDI recurrence in recovered CDI patients, suggesting that colonization of bacteria who share a 
similar nutritional requirement with C. difficile can effectively exclude C. difficile (Gerding et 
al., 2015; Wilson & Sheagren, 1983).  
In addition to colonization with nontoxigenic C. difficile, colonization of Clostridium 
bifermentans before introduction of C. difficile also showed protective effect on gnotobiotic mice 
(Girinathan et al., 2020). The metabolomic results of mouse cecal content before C. difficile 
challenge illustrated significant decrease of nutrients in the C. bifermentans colonized group 
compared to the untreated control group. Of specific interest, amino acids (proline and glycine) 
that can be utilized by C. difficile via Stickland fermentation were largely depleted by C. 
bifermentans (Girinathan et al., 2020). Taken together, these studies provide evidence that 
supports the nutrient niche theory, which states that an organism must be able to utilize a subset 
of substances better than all competitors to colonize the intestine (Jenior et al., 2017). This means 
that a susceptible community must have one or more nutrient niches open up after administration 
of antibiotics that C. difficile is then able to fill in.  
1.3.4 Amino acids as an open niche in disrupted commensal microbiome  
C. difficile has been shown to use a coupled amino acid metabolism as its primary pathway to 
yield ATP (Jackson et al., 2006). This coupled amino acid metabolism is termed as Stickland 
fermentation (shown in Fig 1.2 (a)), where within a pair of amino acids, one amino acid is 
oxidatively deaminated as an electron donor while the other amino acid is reductively 
deaminated as an electron acceptor (Bouillaut et al., 2013). Theriot et al. found that increases in 
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glycine, proline, cysteine, isoleucine, valine, leucine and tryptophan, which are required for C. 
difficile germination and growth, is related to susceptibility to CDI (Theriot et al., 2014).  In 
agreement with Theriot et al., another study showed that mice with dysbiotic gut microbiota are 
more susceptible to C. difficile, and this observation is correlated to the elevated concentrations 
of 12 amino acids, including alanine, proline, glycine, leucine and isoleucine, among which 
proline showing the greatest difference (Battaglioli et al., 2018).  
Proline is one of the most efficient Stickland acceptors; proline can be reduced by proline 
reductase (PR) (Jackson et al., 2006). In C. difficile the prd operon encoding PR consists of 
seven genes, details are shown in Fig 1.2 (b) (Bouillaut et al., 2013). prdB is one gene within the 
operon that is predicted to encode a subunit of PR (Bouillaut et al., 2013). In several mouse 
studies, prdB mutants of C. difficile, which are unable to use proline, showed decreased ability to 
colonize as well as a lower TcdB concentration compared to wild type C. difficile,  indicating the 
ability of C. difficile to ferment proline is important to its colonization and virulence (Battaglioli 
et al., 2018; Lopez et al., 2019). Therefore, amino acids, especially proline, could be one of the 
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open nutrient niches important for C. difficile colonization in the intestinal environment after 
antibiotic treatment. 
            1.3.5 Modeling of human fecal microbiome using bioreactors to study C. difficile  
1.3.5.1 Overall strengths and weaknesses of modeling microbiome in vitro 
Since the late 1970s, in vitro models have been used by scientists to study C. difficile 
infection (Onderdonk et al., 1979). In the past decades, multiple systems have been developed 
and evolved into practical alternatives to animal models. Compared to animal models, in vitro 
models allow more precise control, higher throughput, easier operation and avoid the ethical 
issues about welfare of experimental animals (Best et al., 2012). However, the major 
shortcoming of in vitro models is that they cannot mimic interactions between host immune 
systems and gut microbiome during the process of disease development (Guzman-Rodriguez et 
al., 2018). In sections below, more details about several major types of in vitro models will be 
demonstrated.   
1.3.5.2 Batch culture systems 
Batch culture systems are the simplest in vitro system, but they also have the most 
limitations. Batch culture systems are closed system vessels with defined volumes; inoculation of 
feces into sterile media initiates the establishment of microbial communities (Guzman-Rodriguez 
et al., 2018). Since there is no replenishment of nutrients and waste is not removed, this kind of 
model usually are used in short-term studies analyzing microbial dynamics. Fecal emulsion is 
one of the batch culture systems; Borriello and Barclay used this model to study the importance 
of normal gut microbiome in preventing C. difficile colonization (Borriello & Barclay, 1986). 
They studied C. difficile growth in fecal emulsion derived from several groups of subjects, and 
found that fecal emulsion from healthy adults had higher inhibitory effects on C. difficile growth 
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than those from infants, children and geriatric patients while; this inhibition was removed by 
heating or filtration (Borriello & Barclay, 1986). Their study provided evidence that in vitro 
models can be used to examine the resistance of microbial communities to C. difficile infection 
and in studies investigating mechanisms of colonization resistance (Borriello & Barclay, 1986).  
 1.3.5.3 Single vessel continuous flow model  
Compared to batch culture systems, continuous culture models are more physiologically 
relevant (Guzman-Rodriguez et al., 2018). Continuous culture models allow better controlled 
operation as well as prolonged experimental periods since fresh medium is replenished and waste 
is removed at a constant flow rate (Drake & Brogden, 2002). Thus, scientists are able to study 
organisms in an environment more reflective of conditions observed in vivo (Best et al., 2012). 
Freter and Wilson reported that introduction of hamster flora in germfree mice and continuous 
culture system colonized with C. difficile significantly repressed C. difficile growth (Wilson & 
Freter, 1986). They also showed that collection of isolates from hamster flora can repress C. 
difficile growth in both continuous culture model and germfree mice, suggesting that members of 
gut microbiome are responsible for colonization resistance (Wilson & Freter, 1986). 
1.3.5.4 Three-stage continuous flow culture model 
In the three-stage continuous flow model, there are three vessels that operate in a wier 
cascade system that is top-fed with growth medium at a controlled rate; each vessel is controlled 
at a specific pH to mimic the increasing alkalinity in the gut (Freeman et al., 2005). This system 
was validated against the cecal content of sudden death victims (Freeman et al., 2005). The 
three-stage continuous flow model allows the instillation of antibiotics at fecal or biliary levels 
that are reflective of a clinical dosing regimen, so this model has been used to study the ability of 
antibiotics to introduce CDI, and their efficacy as CDI treatments (Best et al., 2012). Wilcox and 
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colleagues used this model and hamster model to determine the efficacy of ramoplanin and 
vancomycin in clindamycin-induced C. difficile infection, and found that results from these two 
models are consistent (Freeman et al., 2005).  
1.3.5.5 Minibioreactors arrays 
Minibioreactor arrays (MBRAs) are a system of parallel single vessel continuous cultures 
that allow high throughput testing while maintaining complex microbial communities. It has 
been developed to operate at a small volume, thus it is easy to set up dozens of microbial 
communities simultaneously in an anerobic chamber to test different conditions with multiple 
replicates (Auchtung et al., 2015). Auchtung et al. demonstrated that MBRAs successfully 
cultured stable and reproducible microbial communities from different fecal donors (Auchtung et 
al., 2015). Using this model, Collins et al. found that dietary trehalose enhances virulence of 
epidemic C. difficile (Collins et al., 2018). Another study used this model demonstrated that 
administration of polyphenols reduces colonization resistance to C. difficile of the microbiome 
but can neutralize cytotoxicity (Mahnic et al., 2020) 
1.4 Conclusion 
C. difficile infections are still a significant problem to public health and research efforts 
are ongoing to understand disease susceptibility and potential treatments. One tool used to study 
risk factors and potential treatments are continuous-flow bioreactors inoculated with fecal 
samples from healthy humans. While these models have been used extensively as described 
above, relatively little is known about the mechanisms through which they prevent C. difficile 
colonization. Understanding these mechanisms are important for knowing how results obtained 
in vitro are likely to translate into human patients. In the next chapter, I will describe approaches 
that we used to show that nutrient niche dynamics can govern C. difficile colonization resistance 
       16
in vitro. Interestingly, I found that while metabolism of the amino acid proline is one important 
nutrient niche, this amino acid is not limiting in all fecal samples tested. Thus, the open nutrient 
niches for C. difficile in susceptible communities are probably distinct from one another across 
patients and further studies are needed to investigate these different nutrient niches and 
mechanisms for C. difficile colonization. Future studies based on this work could use analysis of 
sequence and metabolomics data from communities combined with compound and pathway 
enrichment analysis and the susceptibility of those communities to C. difficile to begin to 
develop predictive models for the important nutrient niches in a specific community and react 
accordingly to assist in preventing or treating CDI.  
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Chapter 2 Investigating amino acids as a potential niche for C. difficile colonization in 
human microbiome colonized minibioreactors 
2.1 Abstract 
C. difficile is a Gram-positive pathogen that is one of the most common causes of health 
care-associated infections in the U.S. C. difficile infection (CDI) can lead to various symptoms 
from mild diarrhea and abdominal pain to pseudomembranous colitis, toxic megacolon and even 
death in more complicated cases. Because of its importance to human health, studies are trying to 
understand risk factors for infection and identify new therapies to treat disease. A “healthy” gut 
microbiome has the ability to protect the host against colonization of C. difficile or other 
pathogens by providing colonization resistance. One proposed mechanism for colonization 
resistance is through competition for nutrients with members of the healthy microbiome.  We 
tested whether competition for nutrients was important for colonization resistance in human fecal 
minibioreactor arrays (MBRAs), an in vitro model of C. difficile colonization resistance that can 
be used to culture fecal communities from different healthy humans. We found that C. difficile 
growth was limited when amino acids were depleted and that proline, an amino acid shown to be 
important in mouse models of infection, was required for growth in some fecal communities and 
not others.  As several previous studies point to proline metabolism as potentially important 
niche during human infections, these results provide further support for use of this model to 
understand factors important for C. difficile colonization that vary across fecal communities and 
can be used for further development of predictive models of important nutrient niches that can be 
modified to prevent or treat CDI. 
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2.2 Introduction 
C. difficile is a Gram-positive, spore forming, toxin-producing anaerobic bacillus that can 
cause C. difficile infection (CDI) by acquisition of its spore through fecal-oral route (Seekatz & 
Young, 2014). The infection can lead to various symptoms from mild diarrhea and abdominal 
pain to pseudomembranous colitis, toxic megacolon and even death in more complicated cases. 
C. difficile was first recognized as causative agent of human disease in 1978 (Bartlett et al., 
1978); now it has become the most common cause of health care-associated infections in the 
U.S. (Lessa et al., 2015). 
Generally, a “healthy” gut microbiome has the ability to protect the host against 
colonization of C. difficile or other pathogens by providing colonization resistance. The gut 
microbiome can mediate colonization resistance through several potential mechanisms that were 
described in detail in Chapter 1. However, the exact mechanisms that enable the intestinal 
microbiome to limit C. difficile growth still remain less well understood and are actively being 
studied. A better understanding of the mechanisms of colonization resistance may provide 
insights to assist identifying at-risk individuals and boost their resistance by gut microbiota 
modification to prevent the spread of CDI. 
The use of antibiotics can decrease or deplete some taxa of bacteria and alter the structure 
of the intestinal microbiome, which may directly lessen the competition for nutrients (Dethlefsen 
& Relman, 2011; Hill et al., 2010). In addition, it has been demonstrated that antibiotic treatment 
induces shifts in gut microbial metabolome and substances increase in abundance that potentially 
in favor of C. difficile sporulation and growth (Theriot et al., 2014). These antibiotic-induced 
changes of microbiome structure and metabolomic profile increase susceptibility to C. difficile 
colonization (Theriot et al., 2014). Unaltered microbial communities resistant to C. difficile 
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colonization provide evidence for the nutrient niches hypothesis states that an organism must be 
able to utilize a subset of substances better than all competitors to colonize the intestine (Jenior et 
al., 2017). This means that after administration of antibiotics, C. difficile is able to fill one or 
more nutrient niches opened up in a susceptible community. 
C. difficile has been shown to use a coupled amino acid metabolism, known as Stickland 
fermentation, as its primary pathway to yield ATP (Jackson et al., 2006). One of the most 
efficient Stickland acceptors in C. difficile is proline, and proline concentration was shown to 
increase after antibiotic treatment in humans (Battaglioli et al., 2018). Further, C. difficile 
mutants unable to use proline due to inactivation of a subunit of proline reductase (∆prdB) 
showed decreased ability to colonize in mouse studies compared to wild type, indicating the 
ability of C. difficile to ferment proline is important to its colonization (Battaglioli et al., 2018; 
Lopez et al., 2019). 
Previous studies had shown that fecal samples cultured in continuous flow bioreactors 
from healthy humans can be used to model C. difficile colonization resistance and antibiotic-
mediated susceptibility and to identify live microbes to treat C. difficile infection (Auchtung et 
al., 2020). While studies showed that competition for nutrient niches was important for 
colonization resistance in continuous-flow bioreactors colonized with mouse cecal contents 
(Wilson & Perini, 1988), it is not known if nutrient competition prevents C. difficile colonization 
across different human fecal communities cultured in vitro, or if other mechanisms, like 
production of bacteriocins or compounds toxic to C. difficile growth prevented colonization.  
In earlier studies (Robinson et al., 2014), it was reported that C. difficile levels declined 
over time in human fecal minibioreactor arrays (MBRAs), suggesting that nutrient competition 
could be important for inhibiting C. difficile growth. We hypothesized that competition for 
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limiting nutrients inhibited C. difficile growth in human fecal communities. Because 
carbohydrates are limited in our human fecal MBRAs and amino acid metabolism is important 
for C. difficile growth in vivo, we also hypothesized that metabolism of amino acids, especially 
proline, could be one of the open nutrient niches important for C. difficile colonization in 
antibiotic-susceptible communities. 
To test our hypothesis, we screened fecal samples from healthy humans to identify 
communities that exhibited resistance to C. difficile colonization in the absence of antibiotics, 
and susceptibility following disruption with the antibiotic clindamycin. We then used 
supplementation of spent culture medium from antibiotic-susceptible communities to determine 
that C. difficile growth was dependent upon supplementation of amino acids across all fecal 
samples tested. To precisely decide if proline metabolism was necessary for C. difficile 
colonization in MBRA communities, we compared levels of wild type, ∆prdB mutant (unable to 
ferment proline), and ∆prdB Ptet-prdB (∆prdB mutant with restored ability to metabolize proline) 
over time in several MBRA communities. The results indicated that proline metabolism was 
required for colonization of some fecal communities but was not required to colonize other 
communities. We also tested whether introduction of Clostridium sporogenes, a bacterium that 
shares a similar nutrient requirement with C. difficile, prior to C. difficile challenge could 
interfere with C. difficile colonization. We found that C. sporogenes failed to prevent C. difficile 
colonization in the two susceptible communities tested. Taken together, our results suggest that 
amino acids could be an important niche for C. difficile colonization in some microbial 
communities while not in the others.  
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2.3 Materials and Methods  
2.3.1 MBRA structure and operation 
Each strip of MBRA consists of 6 separated chambers, each one with an influent port, an 
effluent port and a sample port. The total volume of each reactor is 25 ml and the working 
volume is 15 ml. As a continuous culture system, fresh media was replenished while waste was 
removed at a flow rate of 1.875 ml/h. To make sure the culture was well mixed, each reactor had 
a stir bar rotated continuously during the entire experimental period. Before use, the entire 
MBRA system along with bottled media was autoclaved to sterilize, then transferred into the 
anaerobic chamber at least 72 hours ahead of MBRA inoculation to achieve an anaerobic state. 
To inoculate, the reactors were filled with 15 ml fresh media, then 3 ml of freshly prepared fecal 
slurry was injected using syringe with needle. The preparation of fecal slurry is explained in 
detail below. After inoculation, initial community recovery and establishment was allowed for 
~18 hours prior to the initiation of flow. The entire system was operated in heated anaerobic 
chamber under 37 °C with an atmosphere of 5% CO2-5% H2-90% N2 (Robinson et al., 2014).  
2.3.2 Fecal sample collection, preparation for MBRA experiments 
Fecal samples donated by 7 healthy adults were collected with sterile containers, packed 
with GasPak (BD Biosciences) in sealed containers (8.1-quart; Sterile Ultraseal) on ice, and 
brought into the anaerobic chamber within 24 hours after collection (Robinson et al., 2014). 
Under anaerobic condition, samples were aliquoted into sterile cryovials (12 g/vial) and stored 
under -80 °C. Before MBRA inoculation, samples were brought into anaerobic chamber, 
suspended with anaerobic phosphate buffered saline (25% w/v). The suspension was vortexed 
for 5 min until homogenized, then centrifuged at ~200Xg for 10 minutes to remove large 
particles. The supernatant on top, referred to as the fecal slurry, was collected and used as 
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inoculum for MBRA. Fecal samples were collected from male and female subjects between the 
ages of 19-65 who were otherwise healthy and consented to participate in the study approved by 
the Institutional Review Board of the University of Nebraska-Lincoln (Protocol 18585). 
2.3.3 Strains, media and growth conditions 
For information of bacterial strains used in this study, see Table 2.1. Bioreactor medium 
version 3 (BRM3) was used in all bioreactor experiments. Its complete and nutrient limited 
version was used in growth curve assays (Table 2.2). One liter of BRM3 contained two parts. 
The first part is 1 g tryptone, 2 g proteose peptone, 2 g yeast extract, 0.4 g sodium chloride, 0.5 g 
bovine bile, 1 ml 0.5% hemin, 1 ml 1% magnesium sulfate, 1 ml 1% calcium chloride, 2 ml 
Tween 80 dissolved in 950 ml water, which was autoclaved at 121°C for 60 min. The other part 
contains 47.8 ml water with 0.1 g arabinogalactan, 0.15 g D-cellobiose, 0.15 g maltose, 0.04 g D-
glucose, 0.2 g inulin, 0.2 ml 0.5% vitamin K3, 2 g sodium bicarbonate, 1 ml 4% potassium 
phosphate dibasic, and 1 ml 4% potassium phosphate monobasic, which was filter sterilized and 
added to the first part following autoclaving (Auchtung et al., 2020) 
Taurocholate-cefoxitin-cycloserine (TCCFA) agar was prepared as previously described 
(Robinson et al., 2014) and used to determine levels of C. difficile in MBRAs through serial 
dilution. TCCFA was supplemented with rifampicin (50 µg/ml) and erythromycin (20 µg/ml) for 
Bacterial strain  Comments Source 
CD2015 027 ribotype, hypervirulent strain Robinson et al., 2014 
CD196 027 ribotype, hypervirulent strain Lopez et al., 2020 
CD196 ∆prdB Mutant unable to ferment proline Lopez et al., 2020 
CD196 ∆prdB Ptet-prdB  Complementation of ∆prdB This study 
CD196 rifR Spontaneous rifampicin resistant mutant This study 
Clostridium sporogenes Stickland fermenter ATCC 3584 
Clostridium butyricum Non-Stickland fermenter, probiotic ATCC 19398 
Table 2.1 Bacterial strains 
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plate counting CD2015, rifampicin (12.5 µg/ml) for counting spontaneous rifampicin resistant 
mutant of CD196 used in one set of competition experiments, and lincomycin (20 µg/ml) used to  
Substance  BRM3 AA-limited 
 
YE-limited BRM3 Sugar-limited 
 
Tryptone  1 g -- 1 g 1 g 
Proteose peptone 
 
2 g -- 2 g 2 g 
Yeast extract 2 g 2 g -- 2 g 
NaCl 0.4 g 0.4 g 0.4 g 0.4 g 
Bovine bile 0.5 g 0.5 g 0.5 g 0.5 g 
0.5% hemin 1 ml 1 ml 1 ml 1 ml 
1% MgSO4 1 ml 1 ml 1 ml 1 ml 
1% CaCl2 1 ml  1 ml  1 ml  1 ml  
Tween 80 2 ml 2 ml 2 ml 2 ml 
Arabinogalactan 0.1 g 0.1 g 0.1 g -- 
Cellobiose 0.15 g 0.15 g 0.15 g -- 
Maltose 0.15 g 0.15 g 0.15 g -- 
Glucose 0.04 g 0.04 g 0.04 g -- 
Inulin 0.2 g 0.2 g 0.2 g -- 
0.5% vitamin K3 0.2 ml 0.2 ml 0.2 ml 0.2 ml 
NaHCO3 2 g 2 g 2 g 2 g 
4% K2HPO4 1 ml 1 ml 1 ml 1 ml 
4% KH2PO4 1 ml 1 ml 1 ml 1 ml 
Table 2.2 BRM3 recipe (1L) 
detect ∆prdB mutants in competition experiments. C. difficile was routinely cultured in Brain 
Heart infusion agar and broth supplemented with 5% yeast extract (BHIS). For isolation of 
∆prdB complemented strains (described below), thiamphenicol (15 µg/ml), cefoxitin (250 
µg/ml), and cycloserine (16 µg/ml) were used to select for C. difficile transconjugants. LB agar 
and broth supplemented with appropriate antibiotics (20 µg/ml chloramphenical; 50 µg/ml 
ampicillin) was used for propagation of E. coli for cloning. 
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2.3.4 Construction of prdB complemented ∆prdB mutant  
The prdB gene was amplified by PCR with NEBPhusion enzyme according to 
manufacturer’s recommendation using chromosomal DNA of CD196 as template and primers 5’- 
ATATGAGCTCGAAAATAGAAGGGAGAGGAAATATATGAG-3’ and 5’- 
ATATGGATCCCATTTTAAACGTGAGCTTTATATTCGTAT-3’. Amplifed DNA was 
digested with SacI-HF and BamHI-HF according to manufacturer’s recommendations (NEB) and 
cloned into plasmid pRFP185 (Fagan & Fairweather, 2011) digested with the same enzymes. 
Plasmid and insert were ligated with T4 DNA ligase according to protocol (NEB) and 
transformed into NEB 5alpha high efficiency competent cells according to manufacturer’s 
protocol. Plasmids were purified with Qiaspin miniprep kit according to protocol (Qiagen) and 
sequenced prior to transformation into competent E. coli SD46 cells, which contain the RP4 
helper plasmid for conjugation as described in Collins et al. (Collins et al., 2018) Transformants 
were selected on LB ampicillin chloramphenicol and a single transformant was used for 
conjugation into CD196 ∆prdB strain as described in Collins et al. (Collins et al., 2018). The 
strain was grown on medium containing thiamphenicol except when preparing for use in 
MBRAs and for testing plasmid stability.  
2.3.5 Determination of Ptet-prdB plasmid stability 
Before use of ∆prdB Ptet-prdB in MBRA experiments, we tested its plasmid stability to 
make sure it is stable enough so the prdB gene will be expressed and its ability to ferment proline 
is actually restored. The strain was inoculated in BRM3 broth with thiamphenicol (thi; 15 µg/ml) 
and let grow overnight. The overnight culture was diluted 1:20 in BRM3 broth with 
anhydrotetracycline (0.5 µg/ml; experimental group) and BRM3 broth with thiamphenicol and 
anhydrotetracycline (15 µg/ml and 0.5 µg/ml, respectively; control group) and incubated for 24 
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hrs. In the following two days, cells were diluted 1:20 every 24 hrs for two days for both groups. 
After the third diluted culture grew for 24 hrs, they were 10-fold serially diluted with phosphate 
buffered saline to 10-6. For the diluent from 10-3 to 10-5 of both groups, 100 µl was spread plated 
on plain BHIS and BHIS with thiamphenicol. After overnight incubation, colonies on plates 
were counted. The plasmid stability is calculated with plasmid stability = (colony number of 
experimental group on BHIS Thi / colony number on BHIS) / (colony number of control group 
on BHIS Thi / colony number on BHIS). After three times of 1:20 dilution for every 24 hrs (12 
generations), the calculation results of plasmid stability is 66.7%, which were determined stable 
enough for testing in MBRA.  
2.3.6 Isolation of spontaneous rifampicin-resistant mutant 
Since the wild type (wt) strain of C. difficile 196 is not resistant to the rifampicin 
concentration we normally use (50 µg/ml), we encountered problems when measuring C. difficile 
levels in competition experiments in MBRA (Because wild-type C. difficile levels were 
determined by subtracting the number of ∆prdB lincomycin-resistant colonies from the total 
population, we needed to use a lower estimation of wild type levels (1 colony out of total) for 
early days in experiment). Thus, we decided to select a spontaneous rifampicin-resistant mutant 
of wt CD196. By testing wt CD196 growth in BHIS with multiple concentrations of rifampicin, 
we found that the minimal inhibitory concentration (MIC) of rifampicin to wt CD196 is 2.5 
µg/ml. Overnight wt CD196 culture was spread on TCCFA with 12.5 µg/ml rifampicin (5x of 
MIC), 100 µl culture per plate. Colonies formed after overnight incubation were considered as 
potential spontaneous rifampicin-resistant mutant. Those colonies were re-streaked onto TCCFA 
with 12.5 µg/ml rifampicin and let grow overnight. One colony was picked and inoculated into 
BHIS broth with 12.5 µg/ml rifampicin. Frozen stocks were made from the overnight BHIS 
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culture as well as cell pellet was collected and verified with PCR using C. difficile specific 
primers (5’-TTGAGCGATTTACTTCGGTAAAGA-3’ and 5’-
CCATCCTGTACTGGCTCACCT-3’, amplify C. difficile 16S rRNA). 
2.3.7 Spent medium collection from LBR 
Since we needed a large volume of spent medium for testing and MBRA only contains 
15ml in each reactor, a large bioreactor (LBR) model was used. Each fecal sample was 
inoculated into an LBR. The experiment followed the same experimental timeline shown in Fig. 
2.2(a). On the first day, reactors were filled with fresh BRM3 to 150ml, then inoculated with 20 
ml of of fecal slurry prepared as described above. After ~24hrs, the pump was turned on to start 
flow in reactors at a rate of 18.75 ml/hr. On day 3, clindamycin was added to source medium 
(250 ug/ml final concentration) and continued for 4 days, then switched back to fresh BRM3 for 
one day to wash out clindamycin. 100 ml of culture was removed from each LBR, centrifuged, 
and the supernatant was sterilized by filtration through a 0.2 µm PVDP filter under anaerobic 
conditions. The filtrate, referred to as spent medium, was sealed tightly and stored at -80°C until 
used for testing.  
2.3.8 Growth assay using nutrient-limited medium 
CD2015 growth in 100% fresh BRM3, 100% spent medium and 1:1 spent medium-fresh 
BRM3 mixture were used as control. CD2015 cultures were grown overnight in BRM3 medium. 
Overnight cultures were diluted 1:10 in control and test medium. CD2015 growth in 1:1 mixture 
of spent medium and three groups of nutrient limited-BRM3 (AA-limited BRM3, YE-limited 
BRM3 and Sugar-limited BRM3; details shown in Table 2.2) were obtained to see if there is a 
significant decrease of growth. Each condition had 8 replicates across two independent 
experiments. All growth curves were read with Tecan Sunrise plate reader at optical density of 
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600 nm (OD600) every 10 minutes for at least 24 hours. The maximum background-subtracted 
OD600 value was used as a measurement of growth yield. 
2.3.9 C. difficile invasion in human microbiome colonized MBRA 
Bottles of BRM3 were preincubated at 37 °C in the anaerobic chamber for at least 12 h to 
make sure there was no contamination. Before inoculation, the reactors were filled with 15 ml 
fresh medium and fecal slurry was prepared as described above. The inoculation was 
administrated with sterile needle and syringe, each reactor was injected with 3 ml of 25% w/v 
fecal slurry which resulted in fecal suspensions with a concentration at about 4% w/v. The 
freshly inoculated reactors were allowed to grow for ~18 h before the flow started, which gave 
the communities time to recover and establish. After ~36 h of the initiation of flow, clindamycin 
solution was added to those source bottles to reach a final concentration of 250 µg/ml and the 
treatment lasted for 3.5 days and stopped by switching source to fresh BRM3. After one day of 
termination of clindamycin treatment, C. difficile culture was introduced to each reactor. To 
prepare the C. difficile culture for invasion, BRM3 broth was inoculated with C. difficile and 
incubated at 37 °C overnight. 8 h before C. difficile challenge, a subculture was made by 1:10 
dilution of the overnight culture. The subculture was 1:10 diluted again and used as culture for C. 
difficile challenge. Following challenge, C. difficile level was monitored on day 0, 1, 3, 5 by 
serial dilution and plating on TCCFA plates as indicated above. For competition assays, an equal 
volume of wt and ∆prdB mutant (based upon OD600) was prepared and inoculated into reactors. 
Day 0 values were obtained from the inoculum and used for determination of competitive 
indexes as indicated. In half of the competition experiments for FS515, FS685, and all replicates 
of FS235 and FS228 a spontaneous rifampicin resistant mutant of an otherwise wild type strain 
was used for competition. C. difficile levels were monitored on days 1, 3, and 5 by plating on 
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TCCFA and TCCFA + lincomycin (experiment with wild-type strain) or TCCFA + rifampicin 
and TCCFA + lincomycin (experiment with spontaneous rifampicin resistant mutant). For the 
competition experiment with wild-type CD196 strain, levels of wt were determined by 
subtracting the number of lincomycin-resistant ∆prdB colonies from total colonies, with a 
minimum ration of wild-type:∆prdB colonies set at 0.05 when there were all detected colonies 
were lincomycin-resistant. For studies with Ptet-prdB, anhydrotetracycline was added to the 
medium beginning on day 0 at 0.25 ug/ml and each reactor was dosed with 300 ul BRM3 with 
12.5 ug/ml anhydrotetracycline to keep it at a high enough concentration.  
Fecal Sample Wt ∆prdB ∆prdB/Ptet-prdB Wt/∆prdB 
competition 
FS515 N=12 N=12 N=8 N=6 
FS685 
 
N=10 N=13 N=9 N=6 
FS235 N=5 N=5 N=4 N=3 
FS228 N=4 N=4 N=4 ND 
FS133 N=3 N=3 ND N=3 
FS583 N=3 N=3 ND N=3 
Table 2.3. Replicates tested per fecal sample in each experiment 
2.3.10 C. sporogenes and C. butyricum pre-colonization of MBRAs prior to C. 
difficile challenge 
The experimental timeline is shown in detail in Figure 2.4(a). The pre-colonization of C. 
sporogenes and C. butyricum started one day after the termination of clindamycin treatment. 
Instead of introducing C. difficile at this time point as in other MBRAs experiments, here we 
added 300 µl overnight culture of C. sporogenes or C. butyricum to each reactor. In the 
following two days, overnight culture of C. sporogenes or C. butyricum were added every 24 hrs. 
After three times of dosing C. sporogenes or C. butyricum, MBRAs communities were 
challenged with wild type strain of C. difficile 196. The C. difficile levels were monitored till day 
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5 after C. difficile introduction. Levels of C. sporogenes and C. butyricum were measured prior 
to dosing into reactors and found to be 8.8 x 106 CFU/ml. 
2.3.11 Statistical analysis 
 Statistical analysis was performed in GraphPad Prism version 9.0 as indicated in the 
figure legends. Unless otherwise indicated, a two-tailed, unpaired Student’s t-test with Dunn’s 
correction for unequal variance was used. P-values less than 0.05 are reported.   
2.4 Results and Discussion 
2.4.1 Identification of communities with C. difficile colonization resistance and 
susceptibility 
Previous studies (Auchtung et al., 2020) showed that communities cultured in vitro from 
different healthy human fecal samples are either resistant to C. difficile colonization or 
susceptible to colonization without any antibiotics. It is important to identify communities that 
have indigenous colonization resistance when there is no antibiotic disruption to better 
understand the roles that specific nutrients may play in colonization resistance in MBRAs. 
Therefore, we examined colonization resistance of communities from seven recently donated 
fecal samples from healthy humans in MBRA. Communities were stabilized for one week and 
then inoculated with C. difficile as shown in Figure 2.1 (a). In four of seven tested fecal samples, 
levels of the ribotype 027 strain C. difficile 2015 (CD2015) decreased more than 1000-fold by 
day 5 in culture to an extent that was under our detection limit, indicating these four fecal 
communities have colonization resistance against C. difficile (Fig 2.1 (b)). As shown in more 
detail below, these four communities are susceptible to C. difficile infection following treatment 
with the antibiotic, clindamycin. 
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2.4.2 Nutrient depletion inhibits C. difficile growth in MBRA spent medium  
In initial studies to determine if C. difficile growth is governed by nutrient-niche 
dynamics, we tested C. difficile growth in spent medium. For these studies, we used larger 
volume bioreactors that operate similar to MBRAs to collect large volumes of cell-free spent 
medium from fecal communities that were treated with the antibiotic clindamycin as outlined in 
Figure 2.2(a) and described in Methods. As shown in Figure 2.2 (b)-(d), spent medium itself 
could not support C. difficile growth. However, when cultured in 1:1 mixture of fresh medium 
and spent medium, C. difficile growth in 2 among all 3 tested fecal samples was not significantly 
different compared to growth in 100% fresh medium. (Growth in in the third fecal sample tested 
increased, but was not at the level observed in 100% fresh medium). This indicates that nutrients 
in spent medium were depleted to a level that was too low to support cell growth, but the 
addition of fresh medium could fully (FS228, Fig2.2(b) and FS615, Fig2.2(d)) or partially 
(FS515, Fig2.2(c)) restore growth. Then, we tested if  there is a specific category of nutrient in 
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fresh medium that contributed to its ability to restore growth. We made three groups of nutrient 
limited bioreactor medium (amino acid-limited [AA limit], yeast extract-limited [YE limit], and 
carbohydrate-limited [CA limit]; details shown in Table 2.2) and tested C. difficile growth in 1:1 
mixture of spent medium and nutrient limited-BRM3. The results showed that growth decreased 
significantly when C. difficile was cultured in spent medium from all the three fecal samples 
supplemented with an equal volume of amino acid-limited medium compared to complete 
bioreactor medium. C. difficile growth was also significantly decreased when spent medium from 
FS228 was mixed with carbohydrate-limited medium compared to growth when spent medium 
was mixed with fresh medium. There were no significant differences in C. difficile growth when 
spent medium was mixed with YE-limited medium compared to growth when spent medium was 
mixed with fresh medium in any fecal community. These results suggest C. difficile was not able 
to grow as well mostly due to lack of amino acids, and that amino acid metabolism could be an 
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important nutrient that defines C. difficile colonization niche in clindamycin-treated human fecal 
microbiome colonized MBRAs. 
2.4.3 Proline metabolism is a variable requirement for infection in MBRAs 
Because we found that amino acids could be important nutrient niches for C. difficile, we 
investigated if metabolism of the amino acid proline could be important for C. difficile 
colonization. As described in detail in Chapter 1, recent studies have shown that proline is an 
important amino acid metabolized by C. difficile during mouse infections. In addition, a recent 
study tested the ability of wild type (wt) C. difficile strain 196 and its isogenic mutant unable to 
utilize proline (∆prdB) to grow in the presence of commensal Clostridia species (Lopez et al., 
2020). The authors found that some Clostridia species decreased the advantages C. difficile 
obtained by proline fermentation, while other Clostridia species increased these advantages 
(Lopez et al., 2020), indicating that other Clostridia species could alter C. difficile proline 
metabolism. However, this study was performed in batch culture without the presence of other 
members of the gut microbiota (Lopez et al., 2020). We hypothesized that C. difficile proline 
fermentation could be important for growth in our MBRA communities, which contain 
Clostridia species as well as members of other gut microbiota (Auchtung et al., 2020; Robinson 
et al., 2014). 
To test this hypothesis, we obtained the wt and ∆prdB mutants used by Lopez et al. in 
their study (Lopez et al., 2020) and tested their performance in MBRA microbial communities. 
For these studies, we cultured fecal communities from the four fecal samples shown in Fig. 
2.1(b) to have colonization resistance to C. difficile (FS228, FS235, FS515, FS685) and two fecal 
samples (FS133 and FS583) shown to be susceptible to C. difficile infection in Fig. 2.1(b). All 
six fecal samples were treated with clindamycin as shown in Fig2.3(a) and then challenged with 
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wild-type (wt) or ∆prdB mutant alone or an equal mixture of wt and ∆prdB mutant to measure 
competitive indexes over time. The competitive index is the ratio of wt:∆prdB strains at the end 
of the experiment compared to the ratio of strains at the beginning. Competition experiments can 
be used to show decreased fitness of mutants that cannot be detected when mutant strains are 
cultured alone. Competition experiments were limited to FS133, FS515, FS583, and FS615. 
From these studies, we saw that across all fecal communities combined, ∆prdB mutants declined 
significantly compared to the wt strain by day 3 in culture (Fig. 2.3(b)-(c)) and also had a 
competitive disadvantage over time (Fig. 2.3(d)-(e)). However, there were some variations 
across fecal samples. All four fecal samples that were resistant to C. difficile colonization in the 
absence of clindamycin treatment (Fig. 2.1(b)) had significantly lower growth of ∆prdB mutant 
compared to wild-type on day 5 of infection (Fig. 2.3(l)), whereas the two fecal samples that do 
not have colonization resistance show no significant differences in levels of wild-type or mutant 
strain when cultured individually. Somewhat surprisingly, ∆prdB has a competitive disadvantage 
on day 5 in two of three replicate cultures in FS133 (CI on day 5=2.5, 0.5, and 17.8), indicating 
that there could be some dependence for proline on persistence in these communities. (wt and 
∆prdB strains were not detected in three replicates of FS583 by day 5 of infection as they had 
washed out). These results suggest that proline metabolism can be a nutrient niche occupied by 
C. difficile in some MBRA communities. 
To test whether the ∆prdB mutant is actually disadvantaged due to being unable to 
metabolize proline, we constructed a tetracycline-inducible copy of prdB on a self-replicating 
plasmid to complement ∆prdB as described in Methods. Plasmid stability testing indicated that 
this plasmid was maintained in 66.7% of cells after 12 generations without antibiotic selection, 
indicating that it may be stable enough to persist in MBRA cultures. We tested growth of  
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complemented strains in four fecal communities, FS515, FS685, FS235, and FS228.  In FS515 
and FS685 communities, we saw that there was significantly increased growth of complemented 
strains compared to ∆prdB strains and that modest differences between wt and complemented 
strains were not statistically significant. In FS235 and FS228 strains, there were no significant 
differences between ∆prdB and complemented strains as both strains were detected at low levels. 
Because prdB is expressed from a plasmid that is not 100% stable it is possible that plasmid loss  
was higher in these experiments. Another possibility is that these communities inactivate the 
anhydrotetracycline used to induce gene expression. Future studies should test a copy of the gene 
integrated into the chromosome and expressed under its native promoter to rule out these 
possibilities. However, the results show that at least in some MBRA communities, loss of PrdB 
function is responsible for decreased growth. 
  2.4.4 Commensal Clostridia do not restore colonization resistance 
              In Chapter 1, we described that gnotobiotic mice colonized with Clostridium 
bifermentans, a Stickland fermenter, before introduction of C. difficile developed milder 
symptoms and had a significantly lower death rate (Girinathan et al., 2020). However, in the 
same study, disease severity of CDI in gnotobiotic mice colonized with Clostridium sardiniense, 
a butyrate-producing Clostridia, was enhanced (Girinathan et al., 2020). Since C. bifermentans 
share a similar metabolic profile with C. difficile while C. sardiniense does not, colonization of 
these strains in gnotobiotic mice conditioned the nutritional environment differently, resulted in 
one that disadvantage C. difficile growth and the other favored C. difficile growth, with a 
significant difference of proline concentrations in C. sporogenes-colonize mice (Girinathan et al., 
2020). As this study was completed in vivo without complex gut microbiome, we were interested 
in if similar effect would be observed in MBRA communities. 
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In our experiment, instead of C. bifermentans and C. sardiniense, we used another 
Stickland fermenter, Clostridium sporogenes, and Clostridium butyricum, a non-Stickland 
fermenter that can produce butyrate that used as a probiotic in Asia (Chen et al., 2020). We used 
these strains because both have been tested for use in humans. To complete this experiment in 
MBRA, we altered the timeline of MBRA operation by adding three days of dosing culture of C. 
sporogenes or C. butyricum prior to challenge of wt strain of C. difficile 196 and C. difficile level 
was monitored till day 5 after challenge. Details are shown in Figure 2.4(a) and described in 
Methods. From the results shown in Figure 2.4 (b)&(c), we can see that in two tested fecal 
communities, pre-colonization of C. sporogenes or C. butyricum in FS515 community enhanced 
C. difficile level compared to group without pre-colonization; while in FS685 community, C. 
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difficile level in all three groups stayed at high level till the end of observation period. Since C. 
difficile level was not decreased and even elevated in C. sporogenes colonized group, 
introduction of nutrient competitor of C. difficile may not exert the same effect within complex 
communities that have a more complicate nutrient competition relationship among all members 
than in monocolonized conditions. 
2.5 Discussion and Conclusions 
In this study, we hypothesized that amino acids, especially proline, could be one of the 
open nutrient niches important for C. difficile colonization in susceptible communities cultured 
in human fecal communities. To test our hypothesis, we first compared C. difficile growth in 
spent medium supplemented with complete medium containing all requirements required for C. 
difficile growth and incomplete medium that lacked either amino acids, sugars, or yeast extract. 
Across all three fecal samples tested, we found that C. difficile growth was significantly 
decreased when amino acid availability was limited, which is one reason that we focused on 
amino acid metabolism in MBRA communities. However, limitation of other categories of 
nutrients also led to decreased C. difficile growth in some of tested groups, indicating that C. 
difficile metabolism of sugars may also be a secondary nutrient niche important for growth in 
fecal communities and that there may be more than one nutrient niche available in some 
disrupted communities.  
The data we collected from testing requirements of proline metabolism for C. difficile 
colonization in MBRA communities also supports the idea that C. difficile colonizes different 
nutrient niches across fecal communities. When we compared levels of wild type, ∆prdB mutant 
(unable to ferment proline), and ∆prdB Ptet-prdB (∆prdB mutant with restored ability to 
metabolize proline) in several MBRA communities we found that proline mentalism is only 
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required in colonizing some communities while not in the others. Specifically, we found that 
proline metabolism was not required in communities that were susceptible to C. difficile 
colonization in the absence of antibiotics, suggesting that competition for proline may be one 
important mechanism for inhibiting C. difficile colonization in our MBRA model. As several 
previous studies point to proline metabolism as potentially important niche during human 
infections, these results provide further support for use of this model to understand C. difficile 
colonization dynamics and identify potential treatments.   
We tested whether treating communities with Clostridium sporogenes, which shares a 
similar nutrient requirement with C. difficile, prior to C. difficile challenge would inhibit C. 
difficile colonization. However, we found that C. difficile colonization remained at high levels or 
were enhanced by treatment with C. sporogenes. Since C. difficile levels were not decreased and 
even elevated in C. sporogenes colonized group, introduction of a potential nutrient competitor 
of C. difficile may not exert the same effect within complex communities that have a more 
complicated food web among all members than in mono-colonized conditions in mice. 
Alternatively, C. sporogenes and C. difficile may metabolize different nutrients in our in vitro 
culture conditions. In support of this, we found that C. sporogenes and C. difficile could persist at 
equally high levels when co-cultured together in MBRAs in the absence of a complex 
community (data not shown). A third possibility is that levels of C. sporogenes were too low to 
have an effect. Future studies could test whether introduction of C. sporogenes alters amino acid 
availability and whether colonization with other proline metabolizing organisms such as 
Lactobacillus rhamnosus GG (Kim et al., 2021) or combinations of organisms would be a better 
approach to inhibit C. difficile.    
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   Taken together, our results suggested that amino acids could be an important niche for C. 
difficile colonization in some microbial communities while not in the others.  Differences in 
nutrient niche between human fecal communities is consistent with what has been observed in 
mice treated with different antibiotics (Jenior et al., 2017) and is likely reflective of differences 
observed across human patients. The open nutrient niches for C. difficile in susceptible 
communities are probably more different from one another and further studies are needed to 
investigate these different nutrient niches and mechanisms for C. difficile colonization. Future 
studies based on this work could use analysis of sequence and metabolomics data from 
communities combined with compound and pathway enrichment analysis and the susceptibility 
of those communities to C. difficile to begin to develop predictive models for the important 
nutrient niches in a specific community and react accordingly to assist in preventing or treating 
CDI. 
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